Ondexxya
E852345
Ondexxya is the brand name of andexanet alfa, a reversal agent used to counteract the anticoagulant effects of factor Xa inhibitors in cases of life-threatening or uncontrolled bleeding.
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf |
andexanet alfa
ⓘ
brand name drug ⓘ |
| affectsBiologicalProcess | blood coagulation ⓘ |
| approvedBy |
European Medicines Agency
NERFINISHED
ⓘ
U.S. Food and Drug Administration NERFINISHED ⓘ |
| belongsToRegulatoryProgram | Risk Evaluation and Mitigation Strategy in the United States ⓘ |
| developedBy |
Alexion Pharmaceuticals
NERFINISHED
ⓘ
Portola Pharmaceuticals NERFINISHED ⓘ |
| doesNotReverse |
heparin
ⓘ
low molecular weight heparin ⓘ vitamin K antagonists ⓘ |
| hasActiveIngredient | andexanet alfa NERFINISHED ⓘ |
| hasApprovalYear | 2018 ⓘ |
| hasATCCode | V03AB38 ⓘ |
| hasBlackBoxWarning |
cardiac arrest
ⓘ
ischemic events ⓘ sudden death ⓘ thromboembolic risk ⓘ |
| hasCommonAdverseEffect |
pneumonia
ⓘ
thromboembolic events ⓘ urinary tract infection ⓘ |
| hasContraindication | known hypersensitivity to andexanet alfa ⓘ |
| hasHalfLife | approximately 1 hour ⓘ |
| hasIndication |
reversal of anticoagulant effects of factor Xa inhibitors
ⓘ
treatment of life-threatening bleeding in patients on factor Xa inhibitors ⓘ treatment of uncontrolled bleeding in patients on factor Xa inhibitors ⓘ |
| hasINN | andexanet alfa NERFINISHED ⓘ |
| hasLegalStatus | prescription only ⓘ |
| hasMechanismOfAction |
acts as a decoy factor Xa protein
ⓘ
binds and sequesters factor Xa inhibitors ⓘ reverses anticoagulant activity of factor Xa inhibitors ⓘ |
| hasMolecularTarget | factor Xa inhibitors bound to factor Xa ⓘ |
| hasOnsetOfAction | within minutes of infusion ⓘ |
| hasPharmaceuticalForm | powder for concentrate for solution for infusion ⓘ |
| hasPregnancyCategory | use only if potential benefit justifies potential risk ⓘ |
| hasRouteOfAdministration | intravenous ⓘ |
| hasTradeName | Ondexxya NERFINISHED ⓘ |
| isAdministeredAs | intravenous bolus followed by infusion ⓘ |
| isUsedBySpecialty |
cardiology
ⓘ
emergency medicine ⓘ hematology ⓘ |
| isUsedIn | hospitals ⓘ |
| marketedBy | Alexion Pharmaceuticals NERFINISHED ⓘ |
| requiresMonitoring |
return of bleeding
ⓘ
signs and symptoms of thrombosis ⓘ |
| targetsDrug |
apixaban
NERFINISHED
ⓘ
rivaroxaban NERFINISHED ⓘ |
| targetsDrugClass | direct factor Xa inhibitors ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.